Actinium Pharmaceuticals Inc (ATNM)

[timberwolf7]

any reason to reject the results of the PH 2 and or expect them to be any different in the PH 3?? Is 30% at 1 year, 20% at 2 years vs no survivors from the PH 2 at 2 years in the salvage arm?? Not to mention the shortened time to treatment thanks to the conditioning??
From my recall, the goal was to improve the results of not using it..

insert-text-here

In a Phase 2 clinical study in 58 patients with advanced AML or high-risk myelodysplastic syndrome (MDS) age 50 and older, Iomab-B produced complete remissions in 100% of patients and these patients experienced transplant engraftment at day 28. The overall survival rate of the 36 relapsed or refractory AML patients in the proof of concept study was 30% at one year and approximately 20% at two years. See Iomab-B study results here.